» Articles » PMID: 25194449

Symptomatic Remission and Patient Quality of Life in an Observational Study of Schizophrenia: is There a Relationship?

Overview
Journal Psychiatry Res
Specialty Psychiatry
Date 2014 Sep 8
PMID 25194449
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

This analysis aimed to examine the association between remission and quality of life (QOL) in schizophrenia. In post-hoc analyses of the 3-year, prospective, observational Schizophrenia Outpatients Health Outcomes (SOHO) study, we compared the QOL of patients who achieved symptomatic and clinical remission with those who did not, and the factors associated. Symptomatic remission was defined as achieving a score of ≤3 on the Clinical Global Impression-Schizophrenia (CGI-SCH) scale, maintained for 6 months and without hospitalization. QOL was patient self-rated using the European-QOL. Of the 6516 patients analyzed, 38% were in symptomatic remission 12 months post-baseline and 52% at 36 months. Functional remission remained fairly constant from 12 months to 36 months (22.4% at both time points). At all visits from 12 to 36 months, patient QOL and social functioning were significantly higher for patients in symptomatic remission. QOL was higher in patients in functional remission. Patients with maintained symptomatic remission over the 3-year follow-up had a much greater improvement in QOL than patients with no symptomatic remission or symptomatic remission for part of the period. Factors associated with a better QOL also included paid employment, socially active, a higher CGI-SCH cognitive score, good compliance, and a better baseline QOL.

Citing Articles

Health related quality of life among people with mental illness: The role of socio-clinical characteristics and level of functional disability.

Defar S, Abraham Y, Reta Y, Deribe B, Jisso M, Yeheyis T Front Public Health. 2023; 11:1134032.

PMID: 36875411 PMC: 9978447. DOI: 10.3389/fpubh.2023.1134032.


Investigating the Role of Insight, Decision-Making and Mentalizing in Functional Outcome in Schizophrenia: A Cross-Sectional Study.

Escobedo-Aedo P, Forjan-Gonzalez A, Martinez A, Ruiz-Ruano V, Sanchez-Alonso S, Mata-Iturralde L Behav Sci (Basel). 2022; 12(2).

PMID: 35200280 PMC: 8868582. DOI: 10.3390/bs12020028.


Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.

Pungor K, Bozikas V, Emsley R, Llorca P, Gopal S, Mathews M Ther Adv Psychopharmacol. 2022; 10:2045125320981500.

PMID: 35186258 PMC: 8851108. DOI: 10.1177/2045125320981500.


Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study.

Dubreucq J, Gabayet F, Godin O, Andre M, Aouizerate B, Capdevielle D Schizophr Bull. 2021; 48(2):382-394.

PMID: 34718808 PMC: 8886587. DOI: 10.1093/schbul/sbab114.


Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication.

Larsen-Barr M, Seymour F Ther Adv Psychopharmacol. 2021; 11:2045125321989133.

PMID: 33796264 PMC: 7970681. DOI: 10.1177/2045125321989133.